INNOVIVA, INC. (INVA) Operating Margin
- Operating margin · 12 months: Value 36.95%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | 36.95% | Operating income / revenue. Period ending 2026-06-30. $162.57M ÷ $440.00M × 100 ≈ 36.95% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | 162.57M USD | Operating Income (Loss) |
| Revenue | 440.00M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | 28.66M USD | Research and Development Expense |
| Selling, general and administration | 126.42M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $162.57M | $440.00M | (m) | $28.66M | $126.42M | 36.95% |
| 2026-03-31 | $160.47M | $420.69M | (m) | $31.45M | $118.27M | 38.14% |
| 2025-12-31 | $163.75M | $411.33M | (m) | $30.60M | $113.32M | 39.81% |
| 2025-09-30 | (m) | $388.52M | (m) | $29.71M | $112.52M | (m) |
| 2025-06-30 | (m) | $370.23M | (m) | $19.59M | $111.45M | (m) |
| 2025-03-31 | (m) | $369.84M | (m) | $14.17M | $112.78M | (m) |
| 2024-12-31 | (m) | $358.71M | (m) | $13.65M | $115.69M | (m) |
| 2024-09-30 | (m) | $352.75M | (m) | $12.35M | $110.68M | (m) |
| 2024-06-30 | (m) | $330.50M | (m) | $12.78M | $113.10M | (m) |
| 2024-03-31 | (m) | $311.59M | (m) | $25.21M | $108.90M | (m) |
| 2023-12-31 | (m) | $310.46M | (m) | $33.92M | $98.23M | (m) |
| 2023-09-30 | (m) | $290.43M | (m) | $41.55M | $89.37M | (m) |
| 2023-06-30 | (m) | $290.42M | (m) | $49.29M | $88.54M | (m) |
| 2023-03-31 | (m) | $317.65M | (m) | $48.18M | $76.78M | (m) |
| 2022-12-31 | (m) | $331.34M | (m) | $41.43M | $63.54M | (m) |
| 2022-09-30 | (m) | $373.22M | (m) | $31.49M | (m) | (m) |
| 2022-06-30 | $359.36M | $403.82M | (m) | $20.21M | (m) | 88.99% |
| 2022-03-31 | $373.35M | $396.41M | (m) | $6.37M | (m) | 94.18% |
| 2021-12-31 | $375.10M | $391.87M | (m) | $576.00K | (m) | 95.72% |
| 2021-09-30 | $355.36M | $374.66M | (m) | $755.00K | (m) | 94.85% |
| 2021-06-30 | $345.24M | $365.49M | (m) | $1.32M | (m) | 94.46% |
| 2021-03-31 | $324.49M | $343.63M | (m) | $1.84M | (m) | 94.43% |
| 2020-12-31 | $321.12M | $336.79M | (m) | $1.79M | (m) | 95.35% |
| 2020-09-30 | $309.98M | $322.29M | (m) | $1.57M | (m) | 96.18% |
| 2020-06-30 | $286.34M | $299.35M | (m) | $559.00K | (m) | 95.65% |
| 2020-03-31 | $270.31M | $284.51M | (m) | (m) | (m) | 95.01% |
| 2019-12-31 | $246.36M | $261.02M | (m) | $0.00 | (m) | 94.39% |
| 2019-09-30 | $249.94M | $264.90M | (m) | (m) | (m) | 94.35% |
| 2019-06-30 | $246.81M | $260.83M | (m) | (m) | (m) | 94.63% |
| 2019-03-31 | $249.72M | $263.81M | (m) | (m) | (m) | 94.66% |
| 2018-12-31 | $238.25M | $261.00M | (m) | $0.00 | (m) | 91.28% |
| 2018-09-30 | $227.44M | $250.67M | (m) | $342.00K | (m) | 90.73% |
| 2018-06-30 | $209.80M | $237.63M | (m) | $653.00K | (m) | 88.29% |
| 2018-03-31 | $194.96M | $229.10M | (m) | $1.00M | (m) | 85.09% |
| 2017-12-31 | $183.60M | $217.22M | (m) | $1.35M | (m) | 84.53% |
| 2017-09-30 | $154.86M | $191.31M | (m) | $1.36M | (m) | 80.95% |
| 2017-06-30 | $142.75M | $175.97M | (m) | $1.33M | (m) | 81.12% |
| 2017-03-31 | $120.80M | $149.88M | (m) | $1.35M | (m) | 80.59% |
| 2016-12-31 | $108.99M | $133.57M | (m) | $1.39M | (m) | 81.60% |
| 2016-09-30 | $88.62M | $112.79M | (m) | $1.77M | (m) | 78.57% |
| 2016-06-30 | $69.14M | $93.05M | (m) | $2.03M | (m) | 74.30% |
| 2016-03-31 | $48.37M | $71.23M | (m) | $2.30M | (m) | 67.90% |
| 2015-12-31 | $31.58M | $53.95M | (m) | $2.62M | (m) | 58.54% |
| 2015-09-30 | $14.42M | $38.39M | (m) | $2.67M | (m) | 37.55% |
| 2015-06-30 | $-3.56M | $25.83M | (m) | $4.04M | (m) | -13.78% |
| 2015-03-31 | $-18.46M | $16.11M | (m) | $5.52M | (m) | -114.60% |
| 2014-12-31 | $-33.93M | $8.43M | (m) | $7.50M | (m) | -402.34% |
| 2014-09-30 | $-181.54M | $2.85M | (m) | $125.35M | (m) | -6365.50% |
| 2014-06-30 | $-179.71M | $2.27M | (m) | $125.54M | (m) | -7923.68% |
| 2014-03-31 | $-201.72M | $3.58M | (m) | $142.15M | $62.96M | -5636.21% |
| 2013-12-31 | $-168.86M | $4.76M | (m) | $125.18M | $48.44M | -3549.03% |
| 2013-09-30 | $-150.39M | (m) | (m) | $119.67M | (m) | (m) |
| 2013-06-30 | $-138.50M | (m) | (m) | $113.30M | (m) | (m) |
| 2013-03-31 | $-132.43M | (m) | (m) | $111.11M | (m) | (m) |
| 2012-12-31 | $-13.00M | $135.76M | (m) | $117.90M | (m) | -9.58% |
| 2012-09-30 | $-18.59M | $135.32M | (m) | $122.25M | (m) | -13.74% |
| 2012-06-30 | $-14.45M | $140.32M | (m) | $123.06M | (m) | -10.29% |
| 2012-03-31 | $-2.40M | $145.28M | (m) | $116.31M | (m) | -1.65% |
| 2011-12-31 | $-109.74M | $24.51M | (m) | $103.57M | (m) | -447.69% |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $-78.32M | $24.22M | (m) | $75.07M | (m) | -323.34% |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | $-81.36M | $24.37M | (m) | $77.52M | (m) | -333.80% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |